Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01000025




Registration number
NCT01000025
Ethics application status
Date submitted
21/10/2009
Date registered
22/10/2009
Date last updated
22/08/2023

Titles & IDs
Public title
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
Scientific title
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Secondary ID [1] 0 0
CAN-NCIC-BR26
Secondary ID [2] 0 0
BR26
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PF-00299804
Treatment: Drugs - Placebo

Active Comparator: PF-00299804 - Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Placebo Comparator: Placebo - Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.


Treatment: Drugs: PF-00299804
PF-804 45 mg PO, daily

Treatment: Drugs: Placebo
Placebo 45 mg PO, daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
42 Months
Secondary outcome [1] 0 0
Overall Survival in KRAS-WT Patients
Timepoint [1] 0 0
42 Months
Secondary outcome [2] 0 0
Overall Survival in EGFR-mutant Patients
Timepoint [2] 0 0
42 Months
Secondary outcome [3] 0 0
Progression-free Survival
Timepoint [3] 0 0
42 Months
Secondary outcome [4] 0 0
Objective Response Rate
Timepoint [4] 0 0
42 months
Secondary outcome [5] 0 0
Number of Participants With Toxicity as Measured by NCI CTCAE Version 4.0
Timepoint [5] 0 0
42 Months

Eligibility
Key inclusion criteria
Eligibility Criteria

- Histologically confirmed diagnosis of non-small cell carcinoma of the lung. Patients
must have an adequate histopathology or cytology specimen must consent to release of
all specimens for this protocol, and the centre/pathologist must have agreed to
submission of the specimens.

- Patients must have evidence of disease, but measurable disease is not mandatory. To be
considered evaluable for complete or partial response assessment, patients must have
at least one measurable lesion as follows:

X-ray = 20 mm Spiral CT scan or physical exam = 10 mm (lymph nodes must be = 15 mm in the
short axis); Measurable lesions must be outside a previous radiotherapy field if they are
the sole site of disease, unless disease progression has been documented.

- Male or female, 18 years of age or older.

- ECOG performance status of 0, 1, 2 or 3. Patients with performance status of 3 are
eligible providing that the investigator attests that the patient has a reasonable
life expectancy (= 6 weeks).

- Adequate renal and hepatic functions as defined by the following required laboratory
values obtained within 14 days prior to randomization. If anemic, patients should be
asymptomatic and should not be decompensated.

Creatinine <1.5 upper limit of normal Total bilirubin < 1.5 upper limit of normal ALT
(SGPT) < 2.5 times the upper limit of normal. Note: If clearly attributable to liver
metastasis, ALT (SGPT) values < 5 times the upper limit of normal are permitted.

- Previous Therapy Failure of a treatment regimen is defined as the inability to continue a
regimen for any reason including, but not limited to, progressive disease, toxicity, or
patient request. Up to a maximum of three lines of chemotherapy for advanced/metastatic
disease (defined below) and at least one of erlotinib or gefitinib for advanced/ metastatic
disease (defined below) should have failed.

Exchange of one chemotherapy agent for another within a combination chemotherapy regimen is
not considered a new regimen in the following circumstances

- carboplatin is substituted for cisplatin due to nephrotoxicity

- one agent in the combination regimen is changed due to hypersensitivity occurring in
the first cycle.

Chemotherapy for Advanced/Metastatic Disease:

Patients must have recovered from any reversible toxic effects and at least 21 days must
have elapsed from the last dose and prior to randomization (14 days from the last dose for
chemotherapy regimens administered on a weekly schedule). Further palliative cytotoxic
chemotherapy must not be planned.

Patients < 70 years:

• Must have received 1 and up to a maximum of 3prior chemotherapy regimens (at least one of
the three must have been a combination regimen and at least one must have contained
platinum).

Patients = 70 years (generally accepted as being at the time of the administration of the
first regimen of chemotherapy for advanced disease):

• Must have received 1 and up to a maximum of 3 prior chemotherapy regimens for their
disease. These may have been single agent chemotherapy regimens and a platinum agent is not
required in keeping with current standards of practice.

Adjuvant Chemotherapy: Patients may ALSO have had prior adjuvant therapy for completely
resected disease, providing completed at least 12 months prior to randomization. Adjuvant
regimens < 12 months prior to randomization and combined chemotherapy/radiation regimens
for irresectable locally advanced stage III disease (irrespective of timing), are
considered to be for advanced/metastatic disease and constitute one of the 3 permissible
regimens. Patients must have recovered from any reversible treatment related toxicities
prior to randomization.

EGFR Inhibitor Therapy: Patients may only be enrolled after failure of prior gefitinib or
erlotinib for advanced or metastatic disease. Patients who have received adjuvant gefitinib
or erlotinib for completely resected NSCLC and who have recurred < 12 months after
discontinuing erlotinib or gefitinib are eligible. Patients who received gefitinib or
erlotinib for neoadjuvant therapy only are not eligible. EGFR inhibitor therapy must have
been discontinued at least 21 days prior to randomization. Patients who discontinued prior
gefitinib or erlotinib therapy for severe or life threatening organ toxicity are not
eligible. Patients may also have received other EGFR active agents (such as reversible oral
agents or monoclonal antibodies or vaccines) in addition to erlotinib or gefitinib but may
not have received ANY prior irreversible EGFR inhibitor such as BIBW2992, HKI-272
(neratinib).

Maintenance Therapy: The same chemotherapy or agent/s continued for longer than 4-6 cycles
for the purposes of 'maintenance' is considered one regimen; if another chemotherapy agent
is given with 'maintenance' intent, it is considered a second regimen providing that
'failure' is documented. Patients who received erlotinib or gefitinib with 'maintenance'
intent after completion of 1st line chemotherapy are eligible providing that 'failure' is
documented.

Radiation: Patients may have had prior radiation therapy provided that a minimum of 14 days
has elapsed between the end of radiotherapy and randomization onto the study. (Exceptions
may be made however, for low dose, non-myelosuppressive radiotherapy. Patients must have
recovered from any acute toxic effects from radiation prior to randomization.

Previous Surgery: Previous surgery is permitted provided that wound healing has occurred
and at least 14 days have elapsed (major surgery).

- Patient able (i.e. sufficiently fluent) and willing to complete the quality of life
questionnaires. The baseline assessment must already have been completed. Inability
(illiteracy, loss of sight, or other equivalent reason) to complete the questionnaires
will not make the patient ineligible for the study. However, ability but unwillingness
to complete the questionnaires will make the patient ineligible.

- Patient consent must be appropriately obtained in accordance with applicable local and
regulatory requirements. Each patient must sign a consent form prior to enrollment in
the trial to document their willingness to participate.

- Patients must be accessible for treatment and follow-up. All randomized patients must
be followed and treated at participating centres. Investigators must assure themselves
the patients randomized on this trial will be available for complete documentation of
the treatment, adverse events, and follow-up.

- In accordance with NCIC CTG policy, protocol treatment is to begin within 2 working
days of patient randomization.

Ineligibility Criteria

Patients who fulfill any of the following criteria are not eligible for admission to the
study:

- Patients receiving concurrent treatment with other experimental drugs or anti-cancer
therapy.

- Patients who have experienced untreated and/or uncontrolled cardiovascular conditions
and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart
failure, myocardial infarction within the previous year or cardiac ventricular
arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular
conduction defects). Patients with a significant cardiac history, even if controlled,
should have a LVEF > 50%.

- Patients with untreated brain or meningeal metastases are not eligible (CT scans are
not required to rule this out unless there is a clinical suspicion of CNS disease).
Patients with treated CNS disease who have radiologic or clinical evidence of stable
brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion,
are eligible providing that they are asymptomatic and do not require corticosteroids
(must have discontinued steroids at least 1 week prior to randomization).

- Patients with active or uncontrolled infections, or with serious illnesses or medical
conditions which would not permit the patient to be managed according to the protocol,
including

- Severe dry eye syndrome

- Keratoconjunctivitis sicca

- Sjogren's syndrome

- Severe exposure keratopathy

- Disorders that might increase the risk for epithelium-related complications
(e.g., bullous keratopathy, aniridia, severe chemical burns, neutrophilic
keratitis)

- Uncontrolled inflammatory gastrointestinal diseases (Crohn's, ulcerative colitis
etc.)

- Prior pneumonitis/ILD secondary to EGFR inhibitors

- Mean QTc with Bazetts correction > 470msec in screening ECG or history of familial
long QT syndrome.

- Drugs that are highly dependent on CYP2D6 for metabolism are prohibited, since PF-804
is a potent CYP2D6 inhibitor in in vitro assays. These inhibitors or inducers are
prohibited from 7 days prior to the first dose until the end of treatment with PF-804.
These include: S-metoprolol, propafenone, timolol, amitriptyline, clomipramine,
desipramine, imipramine, paroxetine, haloperidol, risperidone, thioridazine, codeine,
flecainide, mexilletine, tamoxifen, venlafaxine. Lidocaine may be used with clinical
monitoring (including telemetry). Opiates such as morphine, oxycodone, dihydrocodeine,
hydrocodone, and tramadol can be used as substitutes to replace codeine. Use of these
opiates should be monitored for altered analgesia during treatment with PF-804 as they
may be partly metabolized by CYP2D6. If PF-804 is administered with drugs which are
P-glycoprotein (P-gp) substrates and have a narrow therapeutic index, monitoring for
exaggerated effect and/or toxicities is recommended.

- Pregnancy or inadequate contraception. Women must be post-menopausal, surgically
sterile, or use two reliable forms of contraception. Women of child-bearing potential
must have a pregnancy test taken and proven negative within 7 days prior to
randomization. Men must be surgically sterile or use a barrier method of
contraception.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/12/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/11/2015
Sample size
Target
Accrual to date
Final
720
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [3] 0 0
St. George Hospital, Cancer Care Centre - Kogarah
Recruitment hospital [4] 0 0
Prince of Wales Hospital - Randwick
Recruitment hospital [5] 0 0
Royal North Shore Hospital - St. Leonards
Recruitment hospital [6] 0 0
Calvary Mater Newcastle Hospital - Waratah
Recruitment hospital [7] 0 0
Westmead Hospital - Westmead
Recruitment hospital [8] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [9] 0 0
Nambour General Hospital - Nambour
Recruitment hospital [10] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [11] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [12] 0 0
Western Hospital - Footscray
Recruitment hospital [13] 0 0
Frankston Hospital - Peninsula Oncology Centre - Frankston
Recruitment hospital [14] 0 0
Geelong Hospital - Geelong
Recruitment hospital [15] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [16] 0 0
Sir Charles Gairdner Hospital - Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2217 - Kogarah
Recruitment postcode(s) [4] 0 0
2031 - Randwick
Recruitment postcode(s) [5] 0 0
2065 - St. Leonards
Recruitment postcode(s) [6] 0 0
2298 - Waratah
Recruitment postcode(s) [7] 0 0
2145 - Westmead
Recruitment postcode(s) [8] 0 0
4032 - Chermside
Recruitment postcode(s) [9] 0 0
4560 - Nambour
Recruitment postcode(s) [10] 0 0
5000 - Adelaide
Recruitment postcode(s) [11] 0 0
3168 - Clayton
Recruitment postcode(s) [12] 0 0
3011 - Footscray
Recruitment postcode(s) [13] 0 0
3199 - Frankston
Recruitment postcode(s) [14] 0 0
3220 - Geelong
Recruitment postcode(s) [15] 0 0
3084 - Heidelberg
Recruitment postcode(s) [16] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
Argentina
State/province [3] 0 0
B1878dvb Bs. As.
Country [4] 0 0
Argentina
State/province [4] 0 0
Provincia De Buenos Aires
Country [5] 0 0
Argentina
State/province [5] 0 0
Cordoba
Country [6] 0 0
Argentina
State/province [6] 0 0
San Miguel de Tucuman
Country [7] 0 0
Brazil
State/province [7] 0 0
Rio Grande Do Sul
Country [8] 0 0
Brazil
State/province [8] 0 0
Sao Paulo
Country [9] 0 0
Brazil
State/province [9] 0 0
SP
Country [10] 0 0
Brazil
State/province [10] 0 0
Belo Horizonte
Country [11] 0 0
Brazil
State/province [11] 0 0
Centro
Country [12] 0 0
Brazil
State/province [12] 0 0
Salvador
Country [13] 0 0
Canada
State/province [13] 0 0
Alberta
Country [14] 0 0
Canada
State/province [14] 0 0
British Columbia
Country [15] 0 0
Canada
State/province [15] 0 0
New Brunswick
Country [16] 0 0
Canada
State/province [16] 0 0
Newfoundland and Labrador
Country [17] 0 0
Canada
State/province [17] 0 0
Nova Scotia
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
Canada
State/province [20] 0 0
Saskatchewan
Country [21] 0 0
Italy
State/province [21] 0 0
PN
Country [22] 0 0
Italy
State/province [22] 0 0
VA
Country [23] 0 0
Italy
State/province [23] 0 0
Benevento
Country [24] 0 0
Italy
State/province [24] 0 0
Fano
Country [25] 0 0
Italy
State/province [25] 0 0
Genova
Country [26] 0 0
Italy
State/province [26] 0 0
Meldola
Country [27] 0 0
Italy
State/province [27] 0 0
Messina
Country [28] 0 0
Italy
State/province [28] 0 0
Milan
Country [29] 0 0
Italy
State/province [29] 0 0
Mirano
Country [30] 0 0
Italy
State/province [30] 0 0
Napoli
Country [31] 0 0
Italy
State/province [31] 0 0
Padova
Country [32] 0 0
Italy
State/province [32] 0 0
Palermo
Country [33] 0 0
Italy
State/province [33] 0 0
Piacenza
Country [34] 0 0
Italy
State/province [34] 0 0
Rome
Country [35] 0 0
Italy
State/province [35] 0 0
San Giovanni Rotondo
Country [36] 0 0
Italy
State/province [36] 0 0
Sondalo
Country [37] 0 0
Korea, Republic of
State/province [37] 0 0
GyeongGi-Do
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Jeongnam
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Seoul
Country [40] 0 0
New Zealand
State/province [40] 0 0
Auckland
Country [41] 0 0
Peru
State/province [41] 0 0
Lima
Country [42] 0 0
Philippines
State/province [42] 0 0
Cebu City
Country [43] 0 0
Philippines
State/province [43] 0 0
Makati City
Country [44] 0 0
Philippines
State/province [44] 0 0
Manila
Country [45] 0 0
Taiwan
State/province [45] 0 0
Taichung
Country [46] 0 0
Taiwan
State/province [46] 0 0
Tainan
Country [47] 0 0
Taiwan
State/province [47] 0 0
Taipei
Country [48] 0 0
Thailand
State/province [48] 0 0
Bangkok
Country [49] 0 0
Thailand
State/province [49] 0 0
Chiangmai

Funding & Sponsors
Primary sponsor type
Other
Name
NCIC Clinical Trials Group
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Pfizer
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. It is not yet known whether PF-00299804 is more effective than a
placebo in treating patients with advanced non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying PF-00299804 to see how well it works
compared with a placebo in treating patients with stage IIIB or stage IV non-small cell lung
cancer that has not responded to standard therapy for advanced or metastatic cancer.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01000025
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Peter Ellis, MD
Address 0 0
Margaret and Charles Juravinski Cancer Centre
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01000025